Cu 3 : Glutathione Peptide l hng ca nc no
The clinic provided excellent care and tailored the treatment to my needs
(Wilding JPH et al., NEJM 2021) The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with existing cardiovascular disease and overweight or obesity but without diabetes (Lincoff AM et al., NEJM 2023)
It states that the compounded semaglutide products provided by Noom are not approved by FDA and that they have not undergone review for safety, efficacy, or quality before being dispensed. Being clear about that limitation is the right call, and Noom does it plainly
While there is a lot of information available, there is also a lot of misinformation about what they are, who should take them, and their risks (among other things)